Document Detail

TNK-tPA (tenecteplase).
MedLine Citation:
PMID:  20635756     Owner:  NLM     Status:  MEDLINE    
Management of acute myocardial infarction (AMI) has undergone seismic changes in the last two decades, primarily with the global availability of thrombolytic agents and with the burgeoning use of Primary PCI. Application of these two modalities has dramatically reduced both the mortality and morbidity from AMI. Advances in thrombolytic therapy have been noteworthy in three areas: firstly, in genetically engineering superior third-generation lytic agents: secondly, in developing protocols of appropriate use, and thirdly, creating unambiguous guidelines for admninistration of thrombolytics, of utilizing Primary PCI, or hybrid strategies. Our submitted review on thrombolytic therapy builds on this scientific progress. It provides a pertinent historical perspective that elucidates discovery of lytic agents and the vast array of biogenetic inventions that lead to the development of the novel agent, tenecteplase. The review manuscript also provides a comprehensive compendium of the numerous clinical trials that have been methodically presented in easy-to-read tables. We have additionally designed these tables to facilitate comparison of different lytic agents and for critical analysis of the individual clinical trials. Finally, to make this review most relevant for the IHJ, a section has been devoted to the use of thrombolytic therapy in India. Unique attributes of tenecteplase have been discussed and the benefits of using it to treat Indian patients have been highlighted.
Sameer Mehta; Estefanía Oliveros; Salomon Cohen; Esther Falcão; Ana I Flores
Related Documents :
7585736 - Aggressive interventional treatment of acute myocardial infarction. lessons from the an...
12717496 - Right ventricular wall hematoma due to thrombolytic therapy presenting as cardiac tampo...
2121176 - The management of suspected myocardial infarction by scottish general practitioners wit...
1452916 - Invasive versus conservative strategy after thrombolytic therapy for acute myocardial i...
19144686 - Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulatio...
2436156 - Hemodynamic findings during sinus rhythm, atrial and av sequential pacing compared to v...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Indian heart journal     Volume:  61     ISSN:  0019-4832     ISO Abbreviation:  Indian Heart J     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374675     Medline TA:  Indian Heart J     Country:  India    
Other Details:
Languages:  eng     Pagination:  422-32     Citation Subset:  IM    
Miller School of Medicine, University of Miami & Mercy Medical Center, Miami, Florida, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use
Myocardial Infarction / drug therapy*,  therapy
Randomized Controlled Trials as Topic
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/tenecteplase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Echocardiographic assessment of right heart hemodynamics.
Next Document:  Pre-hospital thrombolysis.